Burning Rock Biotech Limited

22.78-1.26-5.24%Vol 292.47K1Y Perf -11.92%
Jul 30th, 2021 16:00 DELAYED
BID22.72 ASK22.78
Open23.22 Previous Close24.04
Pre-Market- After-Market-
 - -  - -%
Target Price
38.35 
Analyst Rating
— — 0.00
Potential %
68.35 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     50.53
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     48.60
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap2.38B 
Earnings Rating
Price Range Ratio 52W %
20.07 
Earnings Date
10th Aug 2021

Today's Price Range

22.0423.50

52W Range

18.5239.75

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-14.36%
1 Month
-22.67%
3 Months
-25.31%
6 Months
-24.49%
1 Year
-11.92%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BNR22.78-1.2600-5.24
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.14-0.25-78.57
Q04 2020-0.16-0.23-43.75
Q03 2020-0.11-0.18-63.64
Q02 2020-0.20-0.38-90.00
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date10th Aug 2021
Estimated EPS Next Report-0.14
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume292.47K
Shares Outstanding104.55M
Trades Count3.12K
Dollar Volume10.00M
Avg. Volume372.82K
Avg. Weekly Volume594.07K
Avg. Monthly Volume274.15K
Avg. Quarterly Volume390.27K

Burning Rock Biotech Limited (NASDAQ: BNR) stock closed at 22.78 per share at the end of the most recent trading day (a -5.24% change compared to the prior day closing price) with a volume of 293.37K shares and market capitalization of 2.38B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 753 people. Burning Rock Biotech Limited CEO is Yusheng Han.

The one-year performance of Burning Rock Biotech Limited stock is -11.92%, while year-to-date (YTD) performance is -1.39%. BNR stock has a five-year performance of %. Its 52-week range is between 18.52 and 39.75, which gives BNR stock a 52-week price range ratio of 20.07%

Burning Rock Biotech Limited currently has a PE ratio of -22.90, a price-to-book (PB) ratio of 7.89, a price-to-sale (PS) ratio of 40.41, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.75%, a ROC of -33.01% and a ROE of -35.78%. The company’s profit margin is -97.54%, its EBITDA margin is -112.10%, and its revenue ttm is $57.41 Million , which makes it $0.66 revenue per share.

Of the last four earnings reports from Burning Rock Biotech Limited, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Burning Rock Biotech Limited’s next earnings report date is 10th Aug 2021.

The consensus rating of Wall Street analysts for Burning Rock Biotech Limited is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Burning Rock Biotech Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Burning Rock Biotech Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Burning Rock Biotech Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 21.66, ATR14 : 1.93, CCI20 : -110.69, Chaikin Money Flow : 0.01, MACD : -1.56, Money Flow Index : 40.24, ROC : -18.18, RSI : 39.85, STOCH (14,3) : 42.26, STOCH RSI : 0.66, UO : 41.95, Williams %R : -57.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Burning Rock Biotech Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and LungPlasma. The company has developed various cancer detection products , involving tumor targeting, oncomitant diagnosis of immune drugs, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress and detection of tumor sensitivity.

CEO: Yusheng Han

Telephone: +86 2034037871

Address: No. 7, Luoxuan 4th Road, Guangzhou 510005, , CN

Number of employees: 753

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

56%44%

Bearish Bullish

69%31%

News

Stocktwits